Councils & Committees

​Pharmacy and Therapeutics (P&T) Committee

P&T Committee Meeting Information

Upcoming Meetings

Dates

  • Tuesday, September 10, 2024; 12 p.m.-4 p.m.
  • Wednesday, September 11, 2024; 9 a.m.-4 p.m. 

Location

The September P&T Committee meetings will be held virtually

Register for the Webinars

Public Testimony

All members of the public may register to provide verbal or written testimony related to a drug or class of drugs included on the Statewide PDL at the P&T Committee meetings. Registration to present testimony during the meetings must be received by Tuesday, August 27, 2024. To register, please go to www.papdl.com and select "Public Testimony Registration." Written testimony will be accepted and must be submitted by Tuesday, August 27, 2024. Written testimony submissions will be distributed to all P&T Committee members prior to the meetings. All written testimony should be emailed to ra-pharmforms@pa.gov.

Drug Classes

Acne Agents, Oral

Colony Stimulating Factors

Migraine Acute Treatment Agents

Acne Agents, Topical

Continuous Glucose Monitors Products

Migraine Prevention Agents

Alcohol Use Disorder Agents

Contraceptives, Oral

Monoclonal Antibodies (MABs) – Anti-IL, Anti-IgE, Anti-TSLP

Alzheimer’s Agents

Contraceptives, Other

Multiple Sclerosis Agents

Analgesics, Non-Opioid Barbiturate Combinations

COPD Agents

Neuropathic Path Agents

Analgesics, Opioid Long-Acting

Cytokine and CAM Antagonists

NSAIDs

Analgesics, Opioid Short-Acting

Dry Eye Treatments

Obesity Treatment Agents

Androgenic Agents

Enzyme Replacement, Gaucher Disease

Oncology Agents, Breast Cancer

Angiotensin Modulator Combinations

Epinephrine, Self-Injected

Oncology Agents, Oral

Angiotensin Modulators

Erythropoiesis Stimulating Agents

Ophthalmics, Allergic Conjunctivitis

Antianginal Agents

Estrogens

Ophthalmics, Antibiotics

Antibiotics, GI and Related Agents

Fluoroquinolones, Oral

Ophthalmics, Antibiotic-Steroid Combinations

Antibiotics, Inhaled

GI Motility, Chronic Agents

Ophthalmics, Anti-Inflammatories

Antibiotics, Topical

Glucocorticoids, Inhaled

Ophthalmics, Glaucoma

Anticoagulants

Glucocorticoids, Oral

Opioid Overdose Agents

Anticonvulsants

Growth Hormones

Opioid Use Disorder Treatments

Antidepressants, Other

H. Pylori Treatments

Otic Antibiotic Preparations

Antidepressants, SSRIs

Hematopoietic Mixtures

Pancreatic Enzymes

Antiemetics/Antivertigo Agents

Hepatitis B Agents

Penicillins

Antifibrotic Respiratory Agents

Hepatitis C Agents

Phosphate Lowering Agents

Antifungals, Oral

Hereditary Angioedema (HAE) Agents

Pituitary Suppressive Agents, LHRH

Antifungals, Topical

Histamine 2 Receptor Blockers

Platelet Aggregation Inhibitors

Antihemophilia Agents

HIV/AIDS Antiretrovirals

Potassium Removing Agents

Antihistamines, Minimally Sedating

Hypoglycemia Treatments

Prenatal Vitamins

Antihypertensives, Sympatholytic

Hypoglycemics, Alpha-Glucosidase Inhibitors

Progestational Agents

Antihyperuricemics

Hypoglycemics, Incretin Mimetics/Enhancers

Proton Pump Inhibitors (PPIs)

Antimalarials

Hypoglycemics, Insulin and Related Agents

Pulmonary Hypertension Agents, Oral and Inhaled

Antiparasitics, Topical

Hypoglycemics, Meglitinides

Sedative Hypnotics

Antiparkinson’s Agents

Hypoglycemics, Metformins

Sickle Cell Anemia Agents

Antipsoriatics, Oral

Hypoglycemics, SGLT2 Inhibitors

Skeletal Muscle Relaxants

Antipsoriatics, Topical

Hypoglycemics, Sulfonylureas

Smoking Cessation Products

Antipsychotics

Hypoglycemics, TZDs

Steroids, Topical

Antivirals, CMV

Immunomodulators, Atopic Dermatitis

Stimulants and Related Agents

Antivirals, Herpes

Immunomodulators, Topical

Tetracyclines

Antivirals, Influenza

Immunosuppressives, Oral

Thalidomide and Derivatives

Anxiolytics

Intra-Articular Hyaluronates

Thrombopoietics

Benign Prostatic Hyperplasia (BPH) Treatments

Intranasal Rhinitis Agents

Thyroid Hormones

Beta Blockers

Iron Chelating Agents

Tubeless Insulin Delivery Devices

Bile Salts

Iron, Parenteral

Ulcerative Colitis Agents

Bladder Relaxant Preparations

Leukotriene Modifiers

Urea Cycle Disorder Agents

Blood Glucose Meters and Test Strips

Lipotropics, Other

Urinary Anti-Infectives

Bone Density Regulators

Lipotropics, Statins

Vaginal Anti-Infectives

Botulinum Toxins

Local Anesthetics, Topical

Vitamin D Analogs

Bronchodilators, Beta Agonists

Macrolides

VMAT2 Inhibitors

Calcium Channel Blockers

Macular Degeneration Agents

 

Cephalosporins

Methotrexate

 

Related Links

The Department of Human Services (Department) appointed the P&T Committee to act in an advisory capacity to the Department and the Office of Medical Assistance Programs (OMAP) and provide an unbiased clinical perspective on the Department's Statewide Preferred Drug List (PDL). Recommendations from the committee must be reviewed and approved by the Secretary of the Department of Human Services.

Change Healthcare provides clinical and financial analysis support to the P&T Committee.

Committee Information

Composition and responsibilities of the committee:

  • Comprised of department medical directors, external physicians, pharmacists, consumer advocates, and specialists as needed for drug class reviews.
  • Recommend a clinically-based PDL with an emphasis on effectiveness, safety, and outcomes.
  • Recommend prior authorization guidelines for non-preferred drugs as well as certain preferred drugs using current community standards for prescribing.
  • Recommend Prospective and Retrospective Drug Utilization Review Program Review and Development.

 

Name

Specialty

Independent*

Department**

MCO

Ivonne Acrich, MD

OMHSAS Child/Adolescent Psychiatrist

 

X

 

​Dale Adair, MD, FAPA

​Office of Mental Health & Substance Abuse Services Medical Director

​X

Christopher Antypas, PharmD

Community Pharmacist

X

 

 

Lawrence Appel, MD, SFHM

Medical Director, Office of Long Term Living

 

X

 

Meghan Brenkle, PharmD

PA Health & Wellness Pharmacist  X

Terri Cathers, PharmD,
Chair (tie-breaker vote only)

OMAP Pharmacy Director

 

X

 

​Michael Colvin, PharmD

​AmeriHealth Caritas & Keystone First HealthChoices & Community HealthChoices Pharmacist

​X

Sharon Connor, PharmD

Academic Pharmacist

X

 

 

​Molly DiMatteo, DO

​Family Practitioner

​X

​Oluwatoyin Fadeyibi, PharmD, MPH

​Community Behavioral Health Pharmacist

​X

Andrea Fox, MD

Internist

X

 

 

Mark Fuller, MD

Carelon Health of PA Medical Director      X

Donald Gerhart, RPh

Community Pharmacist

X

 

 

James Hancovsky, RPh, MBA

United Health Care Pharmacy Director

 

 

X

​David Kelley, MD

​OMAP Chief Medical Officer, Office of Medical Assistance Programs

​X

Chen Kenyon, MD, MSHPPediatricianX  

Peter Kreckel, RPh

Community Pharmacist

X

 

 

Renee Licwinko, RPh

Gateway Health Plan Pharmacist

 

 

X

Michele Musheno, RPh, MS

Academic/Hospital Pharmacist

X

 

 

​Geoffrey Neimark, MD

​Community Care Behavioral Health Psychiatrist

​X

Ian Paul, MD, Vice Chair

Pediatrician

X

 

 

Adam Raphael Rom, MD

Family Practitioner

X

 

 

Amy Saracino, DO

OMHSAS Adult Psychiatrist

 

X

 

John Shand, MDPerformCare PA Medical Director  X

​Christopher Squillaro, DO

​Magellan Behavioral Health of PA Medical Director

​X

Kevin Szczecina, RPh

Geisinger Health Plan Pharmacist

 

 

X

​Fallan Vaisberg, PharmD, RPh

​Health Partners Plans Formulary Pharmacist

​X

Andreas Wali, MD

​Cardiologist

​X

Verlyn Warrington, MD

Bariatric Medicine Specialist/Family Medicine Doctor

X

 

 

Lloyd Wertz

Consumer/Family Advocate

X

 

 

​Lauren Zandier, PharmD

​UPMC For You Pharmacist

​X

Vacant

Consumer Representative

X

 

 

* - Independent Members are not employed by the Department
** - Department Members are employed by the Department on a full or part-time basis

Effective August 23, 2024 / Last modified August 16, 2024